Safety Assessment
Through years of accumulation, JOINN has been able to evaluate the safety of biomolecular and chemical small molecule drugs, and has evaluated a number of targeted biomolecular drugs such as Her2, CD20, VEGF, EGFR, CD52, CD19, as well as a number of small molecule drugs such as kinase inhibitors and new dosage forms of paclitaxel.